ReviewTrends in microbiology2021
Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time.
Review in Trends in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.Frontiers in immunology · 2021Pooled it
- In the time of COVID-19: challenges, successes, and lessons learned from studies in cancer patients.Journal of the National Cancer Institute · 2025Article
- Backstage Heroes-Yeast in COVID-19 Research.International journal of molecular sciences · 2024Review
- Single-domain antibodies reveal unique borrelicidal epitopes on the Lyme disease vaccine antigen, outer surface protein A (OspA).Infection and immunity · 2024Article
- Development of SARS-CoV-2 entry antivirals.Cell insight · 2024Review
- Prospects for the computational humanization of antibodies and nanobodies.Frontiers in immunology · 2024Review
- Next generation single-domain antibodies against respiratory zoonotic RNA viruses.Frontiers in molecular biosciences · 2024Review
- A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains.MedComm · 2023Article
- Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update.International journal of biological macromolecules · 2023Review
- A comparison of the binding sites of antibodies and single-domain antibodies.Frontiers in immunology · 2023Article
- Review
- Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.Cell research · 2022Article
- A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.Communications biology · 2022Article
- A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals.Research in veterinary science · 2022Article
- SARS-CoV-2 Antiviral Therapy.Clinical microbiology reviews · 2021Review
- SARS-CoV-2 cell entry and targeted antiviral development.Acta pharmaceutica Sinica. B · 2021Review
- Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies).Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Rapid generation of potent antibodies by autonomous hypermutation in yeast.Nature chemical biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Camelid-derived and synthetic single-domain antibodies (sdAbs) are emerging as potent weapons against the novel coronavirus, SARS-CoV-2. sdAbs are small, compact, thermostable immunoglobulin elements capable of binding targets with subnanomolar affinities. By leveraging the power of phage- and yeast surface-display technologies, rare sdAbs can be isolated from highly diverse and complex antibody libraries. Once in hand, sdAbs can be engineered to improve binding affinity, avidity, target specificities, and biodistribution. In this Opinion piece we highlight a series of sophisticated studies describing the identification of ultrapotent sdAbs directed against the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. We discuss the possible applications of these antibodies in the global fight against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.